| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 208,343 | 69,429 | ||
| Marketable securities | 182,915 | 221,165 | ||
| Other receivables | 4,965 | 2,370 | ||
| Prepaid expenses and other current assets | 5,594 | 6,501 | ||
| Total current assets | 401,817 | 299,465 | ||
| Total property and equipment, at cost | 53,122 | - | ||
| Less accumulated depreciation | 25,524 | - | ||
| Property and equipment, net | 27,598 | 29,052 | ||
| Operating lease right-of-use assets | 25,065 | 25,674 | ||
| Restricted cash | 4,950 | 4,950 | ||
| Other long-term assets | 411 | 445 | ||
| Total assets | 459,841 | 359,586 | ||
| Accounts payable | 14,509 | 5,581 | ||
| Accrued expenses and other current liabilities | 17,902 | 13,767 | ||
| Current deferred revenue | 24,791 | 18,410 | ||
| Current portion of operating lease liability | 4,241 | 4,094 | ||
| Total current liabilities | 61,443 | 41,852 | ||
| Deferred revenue, net of current | 111,894 | 8,059 | ||
| Defined benefit plan liability | 4,740 | 4,558 | ||
| Operating lease liability, net of current | 35,927 | 37,037 | ||
| Total liabilities | 214,004 | 91,506 | ||
| Common stock, 0.0001 par value 500,000,000 shares authorized, 61,790,239 and 61,507,446 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 6 | 6 | ||
| Additional paid-in capital | 680,157 | 675,445 | ||
| Accumulated other comprehensive loss | -3,247 | -3,373 | ||
| Accumulated deficit | -431,079 | -403,998 | ||
| Total stockholders' equity | 245,837 | 268,080 | ||
| Total liabilities and stockholders' equity | 459,841 | 359,586 | ||
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)